Road to Success, July 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, August 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, January 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, October 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, November 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, December 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, December 2005

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, February 2006

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, March 2006

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, May 2006

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

Road to Success, April 2006

Monthly newsletter produced by Iowa Department of Vocational Rehabilitation

El patró “no dipper” i la rigidesa arterial, poden estar relacionats amb les lesions glomerulars incipients dels pacients amb obesitat mòrbida?

La monitorització ambulatòria de la pressió arterial (MAPA) és la millor tècnica pel diagnòstic d’hipertensió arterial i es relaciona millor amb l’afectació d’òrgans diana respecte la pressió arterial clínica. Recentment, s’ha descrit un indicador de rigidesa arterial que s’ estima a partir de la MAPA, l’ Ambulatory Arterial Stiffnes Index (AASI). En aquest treball es valora si els pacients amb obesitat mòrbida presenten rigidesa arterial mesurada a través de la MAPA i s’identifiquen factors de risc associats amb la lesió glomerular i vascular.

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.

BACKGROUND: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2-7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases. PATIENTS AND METHODS: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal. RESULTS: A median of eight fotemustine infusions per patient were delivered (range 1-26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival. CONCLUSIONS: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 years.

Componentes da síndrome metabólica na hipertensão arterial

Este estudo teve como objetivo identificar e comparar a prevalência da síndrome metabólica entre hipertensos e normotensos. Os aspectos adotados para a definição de síndrome metabólica foram os definidos pelo National Cholesterol Education Program/Adults Treatment Painel (NCEP-ATP III). Os dados referentes aos perfis clínicos e bioquímicos foram processados no programa SPSS para cálculo de frequências absolutas e porcentagens. Utilizou-se o teste t de Student para comparações das médias, sendo as diferenças consideradas estatisticamente significantes para p<0,05. A amostra foi composta por 93 participantes normotensos e 168 hipertensos. Identificou-se a presença de síndrome metabólica em 60,7% dos hipertensos e 18,3% dos normotensos. Os portadores de hipertensão arterial apresentam diferença significante nos valores de pressão arterial (p<0,001), circunferência abdominal (p<0,001), glicemia (p<0,05) e triglicérides plasmáticos (p<0,05). A frequência dos riscos cardiometabólicos associados à síndrome metabólica é maior na presença de doença hipertensiva.